1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
2. Vivier E, Nunès JA, Vély F: Natural killer cell signaling pathways. Science 2004, 306:1517-9.
3. Parham P: MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-14.
4. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L: Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nature Immunol 2008, 9:486-94.
5. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-71. F1000 Factor 14 Evaluated by Wayne Yokoyama 05 Oct 2001, Eric Long 10 Oct 2001, William Heath 18 Oct 2001, Siamak Bahram 23 Nov 2001
6. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH: NKG2D- deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-80. F1000 Factor 10 Evaluated by Glenn Dranoff 15 Apr 2008, Lutz Walter 20 May 2008
7. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-100. F1000 Factor 10 Evaluated by John Cambier 21 Jun 2002
8. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-40. F1000 Factor 6 Evaluated by Frank Christiansen 03 Jul 2007
9. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-9.
10. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, Lifson JD, Allen TM, Carrington M, Altfeld M: Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007, 204:3027-36.
11. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, Miller JS, Carrington M, Altfeld M: HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009, 83:6798-805.
12. Carrington M, Martin MP, van Bergen J: KIR-HLA intercourse in HIV disease. Trends Microbiol 2008, 16:620-7.
13. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O’Brien SJ, Rosenberg WM, Thomas DL, Carrington M: HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-4. F1000 Factor 10 Evaluated by Eric Long 16 Aug 2004, Lewis Lanier 17 Aug 2004
14. Vidal-Castiñeira JR, López-Vázquez A, Díaz-Peña R, Alonso-Arias R, Martínez-Borra J, Pérez R, Fernández-Suárez J, Melón S, Prieto J, Rodrigo L, López-Larrea C: Effect of killer immunoglobulin-like 
15. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B: Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008, 118:1017-26.
16. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P: Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008, 180:3969-79.
17. Witt CS: The influence of NK alloreactivity on matched unrelated donor and HLA identical sibling haematopoietic stem cell transplantation. Curr Opin Immunol 2009, 21:531-7.
18. Raulet DH, Vance RE: Self-tolerance of natural killer cells. Nat Rev Immunol 2006, 6:520-31.
19. Elliott JM, Wahle JA, Yokoyama WM: MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 2010, 207:2073-9.
20. Joncker NT, Shifrin N, Delebecque F, Raulet DH: Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 2010, 207:2065-72.
21. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-42.
22. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann TL, McQueen KL, Guethlein LA, Parham P, and Miller JS: A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007, 110:578-86.
23. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A: Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2010, 117:764-71.
24. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A: Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-29.
25. Haas P, Loiseau P, Tamouza R, Cayuela JM, Moins-Teisserenc H, Busson M, Henry G, Falk CS, Charron D, Socie G, Toubert A, Dulphy N: NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem- cell transplantation. Blood 2010, 117:1021-9.
26. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-9.
27. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002, 100:3825-7.
28. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-32.
29. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, Kögler G, Beguin Y, Navarrete C, Devos T, Ionescu I, Boudjedir K, Herr AL, Gluckman E, Rocha V; Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
30. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O’Reilly RJ, Hsu KC: Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009, 113:3875-84.
31. Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, Pohlman B, Andresen S, Theil KS, Dean R, Bolwell BJ: Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA- Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 2007, 39:417-24.
32. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SEG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-9.
33. Suck G, Koh MB: Emerging natural killer cell immunothera- pies: large-scale ex vivo production of highly potent anti- cancer effectors. Hematol Oncol Stem Cell Ther 3:135-42.
34. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr., Barlogie B, van Rhee F: Infusion of haploidentical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008, 143:641-53.
35. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-7.
36. Siegler U, Meyer-Monard S, Jörger S, Stern M, Tichelli A, Gratwohl A, Wodnar-Filipowicz A, Kalberer CP: Good manufacturing prac- tice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010, 12:750-63.
37. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Bjorkstrom NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringdén O, Ljunggren HG, Dilber MS: Safety analysis of ex vivo-expanded NK and NK- like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009, 1:753-64.
38. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-7.
39. Berg M, Lundqvist A, McCoy P Jr., Samsel L, Fan Y, Tawab A, Childs R: Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-55.
40. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
41. ClinicalTrials.gov – A phase I study of intravenous recombinant human IL-15 in adults with refractory metastatic malignant melanoma and metastatic renal cell cancer. [
42. Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI; Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group: Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand 
43. Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr., Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N: Preclinical characterization of 1-7F9, a novel human antiKIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-77.
44. Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-90. F1000 Factor 17 Evaluated by Lewis Lanier 14 Jul 2005, Lucio Comai 18 Jul 2005, Guy Laurent 08 Aug 2005, Mark Smyth 12 Aug 2005, John Abrams 26 Aug 2005, Lutz Walter 05 Sep 2005
45. Ames E, Hallett WH, Murphy WJ: Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol 2009, 155:504-13.
46. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT: Proteasome regulation of ULBP1 transcription. J Immunol 2009, 182:6600-9.